S&P 500   4,284.15 (+0.24%)
DOW   34,000.95 (+0.06%)
QQQ   329.22 (+0.22%)
AAPL   174.25 (-0.17%)
MSFT   290.44 (-0.30%)
META   174.48 (-0.21%)
GOOGL   120.22 (+0.56%)
AMZN   142.09 (+-0.01%)
TSLA   908.04 (-0.43%)
NVDA   187.43 (+2.23%)
NIO   19.92 (-0.80%)
BABA   90.60 (+0.92%)
AMD   100.44 (+2.21%)
MU   62.98 (+2.21%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.16 (+0.81%)
GE   79.42 (-0.63%)
DIS   122.69 (-0.10%)
AMC   19.15 (-10.35%)
PYPL   99.86 (+0.44%)
PFE   48.63 (-1.30%)
NFLX   245.13 (+1.65%)
S&P 500   4,284.15 (+0.24%)
DOW   34,000.95 (+0.06%)
QQQ   329.22 (+0.22%)
AAPL   174.25 (-0.17%)
MSFT   290.44 (-0.30%)
META   174.48 (-0.21%)
GOOGL   120.22 (+0.56%)
AMZN   142.09 (+-0.01%)
TSLA   908.04 (-0.43%)
NVDA   187.43 (+2.23%)
NIO   19.92 (-0.80%)
BABA   90.60 (+0.92%)
AMD   100.44 (+2.21%)
MU   62.98 (+2.21%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.16 (+0.81%)
GE   79.42 (-0.63%)
DIS   122.69 (-0.10%)
AMC   19.15 (-10.35%)
PYPL   99.86 (+0.44%)
PFE   48.63 (-1.30%)
NFLX   245.13 (+1.65%)
S&P 500   4,284.15 (+0.24%)
DOW   34,000.95 (+0.06%)
QQQ   329.22 (+0.22%)
AAPL   174.25 (-0.17%)
MSFT   290.44 (-0.30%)
META   174.48 (-0.21%)
GOOGL   120.22 (+0.56%)
AMZN   142.09 (+-0.01%)
TSLA   908.04 (-0.43%)
NVDA   187.43 (+2.23%)
NIO   19.92 (-0.80%)
BABA   90.60 (+0.92%)
AMD   100.44 (+2.21%)
MU   62.98 (+2.21%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.16 (+0.81%)
GE   79.42 (-0.63%)
DIS   122.69 (-0.10%)
AMC   19.15 (-10.35%)
PYPL   99.86 (+0.44%)
PFE   48.63 (-1.30%)
NFLX   245.13 (+1.65%)
S&P 500   4,284.15 (+0.24%)
DOW   34,000.95 (+0.06%)
QQQ   329.22 (+0.22%)
AAPL   174.25 (-0.17%)
MSFT   290.44 (-0.30%)
META   174.48 (-0.21%)
GOOGL   120.22 (+0.56%)
AMZN   142.09 (+-0.01%)
TSLA   908.04 (-0.43%)
NVDA   187.43 (+2.23%)
NIO   19.92 (-0.80%)
BABA   90.60 (+0.92%)
AMD   100.44 (+2.21%)
MU   62.98 (+2.21%)
T   18.42 (+0.00%)
CGC   3.79 (-6.65%)
F   16.16 (+0.81%)
GE   79.42 (-0.63%)
DIS   122.69 (-0.10%)
AMC   19.15 (-10.35%)
PYPL   99.86 (+0.44%)
PFE   48.63 (-1.30%)
NFLX   245.13 (+1.65%)
NASDAQ:AKTX

Akari Therapeutics - AKTX Stock Forecast, Price & News

$1.42
-0.04 (-2.74%)
(As of 08/18/2022 11:08 AM ET)
Add
Compare
Today's Range
$1.42
$1.42
50-Day Range
$0.83
$1.59
52-Week Range
$0.75
$1.88
Volume
3 shs
Average Volume
111,205 shs
Market Capitalization
$84.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKTX stock logo

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics Stock Performance

AKTX Stock opened at $1.42 on Thursday. The firm has a market cap of $84.28 million, a price-to-earnings ratio of -3.94 and a beta of 1.28. The firm has a 50-day simple moving average of $1.08 and a two-hundred day simple moving average of $1.16. Akari Therapeutics has a one year low of $0.75 and a one year high of $1.88.

Akari Therapeutics (NASDAQ:AKTX - Get Rating) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.12) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a research note on Wednesday. They issued a "sell" rating on the stock.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Akari Therapeutics Narrows Pipeline Focus
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Akari Therapeutics net loss of $17.4M
Akari Therapeutics slips on $9M equity offering
Akari Therapeutics picks new CEO
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings
3/31/2020
Today
8/18/2022
Next Earnings (Estimated)
9/28/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Profitability

Net Income
$-17,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.11 per share

Miscellaneous

Free Float
22,671,000
Market Cap
$84.28 million
Optionable
Not Optionable
Beta
1.28

Key Executives

  • Dr. Ray Prudo-Chlebosz M.D. (Age 77)
    Exec. Chairman
    Comp: $618k
  • Dr. Torsten Hombeck (Age 52)
    Chief Financial Officer
    Comp: $454.88k
  • Ms. Rachelle Suzanne Jacques (Age 51)
    Pres, CEO & Director
  • Ms. Melissa Bradford-Klug
    Chief Operating Officer
  • Dr. Miles Nunn
    Chief Scientific Officer
  • Annie Mack
    Financial Controller













AKTX Stock - Frequently Asked Questions

How have AKTX shares performed in 2022?

Akari Therapeutics' stock was trading at $1.50 at the start of the year. Since then, AKTX stock has decreased by 5.3% and is now trading at $1.42.
View the best growth stocks for 2022 here
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 28th 2022.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.25.

What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include LPL Financial LLC (0.14%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.42.

How much money does Akari Therapeutics make?

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $84.28 million. The biopharmaceutical company earns $-17,420,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.